SIPA1L2基因变异与CMT1A表型修饰相关
研究纳入971例经基因分型的CMT1A患者,对330例足背屈肌力极端表型者行全基因组分析,发现SIPA1L2四个SNP与足背屈肌力显著相关(p < 1×10-7)。功能实验提示SIPA1L2受SOX10调控、与β-actin和MYH9结合,敲低后PMP22表达下降。
要点
- SIPA1L2四个SNP与CMT1A足背屈肌力相关(p < 1×10-7)。
- SIPA1L2受SOX10调控并参与髓鞘化共表达网络。
- 敲低SIPA1L2可降低PMP22表达,提示潜在治疗方向。
核心结论
- SIPA1L2是CMT1A表型表达的潜在遗传修饰因子,并提供新的治疗干预路径。
研究设计与样本
- 遗传性神经病联盟历时8年收集971例CMT1A患者的标准化样本,用Illumina BeadChips进行基因分型。
- 对330例足背屈肌力轻度与重度极端表型患者进行全基因组分析。
- 采用免疫共沉淀、质谱和免疫细胞化学验证相互作用蛋白,并用染色质免疫沉淀和体外siRNA实验分析基因调控。
主要发现
- SIPA1L2的4个单核苷酸多态性(rs10910527、rs7536385、rs4649265、rs1547740)与足背屈肌力显著相关(p < 1×10-7)。
- 免疫共沉淀和质谱鉴定β-actin与MYH9为SIPA1L2结合伙伴。
- SIPA1L2属于受主转录因子SOX10调控的髓鞘化相关共表达网络。
- 在Schwann瘤细胞中体外敲低SIPA1L2导致PMP22表达显著降低。
临床怎么用
- SIPA1L2变异可作为CMT1A表型严重程度的潜在遗传修饰标志。
- SIPA1L2-PMP22调控轴提示可探索针对该通路的治疗干预。
局限性
- 全基因组分析仅基于330例极端表型患者,样本量有限。
- SIPA1L2作为修饰基因的临床效用尚需独立队列验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Genetic modifiers in rare disease have long been suspected to contribute to the considerable variance in disease expression, including Charcot-Marie-Tooth disease type 1A (CMT1A). To address this question, the Inherited Neuropathy Consortium collected a large standardized sample of such rare CMT1A patients over a period of 8 years. CMT1A is caused in most patients by a uniformly sized 1.5 Mb duplication event involving the gene PMP22. METHODS: We genotyped DNA samples from 971 CMT1A patients on Illumina BeadChips. Genome-wide analysis was performed in a subset of 330 of these patients, who expressed the extremes of a hallmark symptom: mild and severe foot dorsiflexion strength impairment. SIPA1L2 (signal-induced proliferation-associated 1 like 2), the top identified candidate modifier gene, was expressed in the peripheral nerve, and our functional studies identified and confirmed interacting proteins using coimmunoprecipitation analysis, mass spectrometry, and immunocytochemistry. Chromatin immunoprecipitation and in vitro siRNA experiments were used to analyze gene regulation. RESULTS: We identified significant association of 4 single nucleotide polymorphisms (rs10910527, rs7536385, rs4649265, rs1547740) in SIPA1L2 with foot dorsiflexion strength (p < 1 × 10-7 ). Coimmunoprecipitation and mass spectroscopy studies identified β-actin and MYH9 as SIPA1L2 binding partners. Furthermore, we show that SIPA1L2 is part of a myelination-associated coexpressed network regulated by the master transcription factor SOX10. Importantly, in vitro knockdown of SIPA1L2 in Schwannoma cells led to a significant reduction of PMP22 expression, hinting at a potential strategy for drug development. INTERPRETATION: SIPA1L2 is a potential genetic modifier of CMT1A phenotypic expressions and offers a new pathway to therapeutic interventions. ANN NEUROL 2019;85:316-330.
引用
- Tao F, Beecham GW, Rebelo AP, et al. Variation in SIPA1L2 is correlated with phenotype modification in Charcot- Marie- Tooth disease type 1A. Ann Neurol. 2019. PMID: 30706531. doi:10.1002/ana.25426
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。